[Morphometric analysis of corneal endothelium after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment]. / Análisis morfométrico del endotelio corneal tras ranibizumab intravítreo en la degeneración macular asociada a la edad.

PURPOSE: To determine the effect of intravitreal injection of 0.5mg ranibizumab on the corneal endothelium in patients with age-related macular degeneration (AMD). METHODS: Observational, prospective case series pilot study. Twenty-six eyes of 26 consecutive patients with AMD were evaluated. All participants received one monthly intravitreal injections of 0.5mg ranibizumab for three consecutive months. The follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed and the central corneal thickness was measured. RESULTS: There were no significant differences in the endothelial cell densities, coefficients of variation of cell size and percentages of hexagonal cells before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P>0.5). There was also no significant difference in central corneal thickness measurements through the follow-up period (P>0.5). CONCLUSIONS: Repeated intravitreal injections of 0.5mg ranibizumab do not seem to cause substantial changes in the corneal endothelium.

Análisis morfométrico del endotelio corneal tras ranibizumab intravítreo en la degeneración macular asociada a la edad / Morphometric analysis of corneal endothelium after intravitreal ranibizumab (Lucentis®) in age-related macular degeneration treatment

ObjetivoEvaluar el efecto de la inyección intravítrea de 0,5mg ranibizumab sobre el endotelio corneal en pacientes con degeneración macular asociada a la edad (DMAE).MétodoEstudio piloto de serie de casos, observacional y prospectivo con observador enmascarado. Veintiséis ojos (26 pacientes) con DMAE fueron evaluados. Todos los pacientes recibieron 1 inyección intravítrea mensual de 0,5mg de ranibizumab durante 3 meses consecutivos. El periodo de seguimiento fue de 6 meses. El endotelio corneal central fue evaluado antes, a los 7 días y a los 6 meses de la primera inyección de ranibizumab con microscopía especular. La densidad de las células endoteliales, coeficiente de variación del tamaño celular y porcentaje de hexagonalidad celular fueron analizados. También fue medido el espesor corneal central.ResultadosNo se encontraron diferencias estadísticamente significativas entre los valores preinyección y postinyección a los 7 días y 6 meses de la primera inyección de ranibizumab en las densidades de células endoteliales, coeficientes de variación del tamaño celular y porcentajes de hexagonalidad celular (p>0,5). Tampoco se encontraron modificaciones significativas en el espesor corneal central a lo largo del periodo de seguimiento (p>0,5).ConclusionesInyecciones intravítreas repetidas de 0,5mg ranibizumab no parecen causar cambios importantes sobre el endotelio corneal a los 6 meses de seguimiento(AU)

PurposeTo determine the effect of intravitreal injection of 0.5mg ranibizumab on the corneal endothelium in patients with age-related macular degeneration (AMD).MethodsObservational, prospective case series pilot study. Twenty-six eyes of 26 consecutive patients with AMD were evaluated. All participants received one monthly intravitreal injections of 0.5mg ranibizumab for three consecutive months. The follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed and the central corneal thickness was measured.ResultsThere were no significant differences in the endothelial cell densities, coefficients of variation of cell size and percentages of hexagonal cells before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P>0.5). There was also no significant difference in central corneal thickness measurements through the follow-up period (P>0.5).ConclusionsRepeated intravitreal injections of 0.5mg ranibizumab do not seem to cause substantial changes in the corneal endothelium(AU)

[Endothelial cells analysis after intraoperative mitomycin-C adjuvant pterygium simple excision surgery: a pilot study]. / Análisis morfométrico del endotelio de la córnea tras aplicación intraoperatoria de mitomicina C en la resección simple de pterigión: un estudio piloto.

PURPOSE: To study the effects of mitomycin-C (MMC) on the corneal endothelium after pterygium surgery. METHODS: Prospective, interventional, nonrandomized, observer-masked study. Twenty patients (20 eyes) with primary pterygium underwent surgery with pterygium simple excision followed by 0.02% MMC application for 1 minute. Preoperative, 10-day, 1-month and 3-month postoperative specular microscopy were performed. Mean cell density, coefficient of variation of mean cell area and percentage of hexagonal cells were measured. RESULTS: Mean endothelial cell densities before and 3 months after surgery were 2,240.37 SD 347.92 cells/mm2 (range: 1,020 to 2,703) and 2,283.86 SD 425.13 cells/mm2 (range: 1,001 to 2,837), respectively. Mean coefficient of variation before and 3 months after surgery were 32.63 SD 4.65 (range: 22 to 48) and 33.00 SD 4.75 (range: 23 to 51), respectively. Mean percentage of hexagonal cells before and 3 months after surgery were 54.58 SD 6.60 (range: 46 to 71) and 55.26 SD 8.89 (range: 38 to 76), respectively. No statistically significant differences were found in any of the parameters studied when compared to the preoperative values. CONCLUSIONS: A single intraoperative application of 0.02% MMC for 1 minute during pterygium simple excision surgery does not seem to cause substantial changes in corneal endothelial cell density at 3 months.

Análisis morfométrico del endotelio de la córnea tras aplicación intraoperatoria de mitomicina C en la resección simple de pterigión: un estudio piloto / Endothelial cells analysis after intraoperative mitomycin-C adjuvant pterygium simple excision surgery: a pilot study

Objetivo: Evaluar el efecto de la mitomicina C (MMC) sobre el endotelio corneal tras cirugíade pterigión.Método: Estudio clínico intervencional y prospectivo con observador enmascarado. Veintepacientes (20 ojos) con pterigión primario fueron intervenidos mediante resección simpledel pterigión y aplicación intraoperatoria de MMC al 0,02% durante 1 minuto. El endoteliocorneal fue evaluado pre- y postoperatoriamente a los 10 días, al mes y a los 3 meses, conmicroscopía especular. La densidad de las células del endotelio corneal, coeficiente devariación del tamaño celular y porcentaje de hexagonalidad celular fueron analizados.Resultados: Las medias de la densidad de células endoteliales antes y a los 3 meses de lacirugía fueron 2.240,37 desviación estándar (DE) 347,92 células/mm2 (rango: 1.020 a 2.703)y 2.283,86 DE 425,13 células/mm2 (rango: 1.001 a 2.837), respectivamente. Las medias delcoeficiente de variación antes y a los 3 meses de la cirugía fueron 32,63 DE 4,65 (rango: 22a 48) y 33,00 DE 4,75 (rango: 23 a 51), respectivamente. Las medias de los porcentajes dehexagonalidad celular antes y a los 3 meses de la cirugía fueron 54,58 DE 6,60 (rango: 46 a71) y 55,26 DE 8,89 (rango: 38 a 76), respectivamente. No se encontraron diferencias estadísticamentesignificativas en las comparaciones con el valor preoperatorio en ninguna delas variables analizadas.Conclusiones: La aplicación intraoperatoria de MMC al 0,02% durante 1 minuto en la resecciónsimple de pterigión no parece causar cambios sustanciales sobre la densidad de lascélulas del endotelio corneal a corto plazo(AU)

To study the effects of mitomycin-C (MMC) on the corneal endothelium afterpterygium surgery.Methods: Prospective, interventional, nonrandomized, observer-masked study. Twentypatients (20 eyes) with primary pterygium underwent surgery with pterygium simpleexcision followed by 0.02% MMC application for 1 minute. Preoperative, 10-day, 1-monthand 3-month postoperative specular microscopy were performed. Mean cell density,coefficient of variation of mean cell area and percentage of hexagonal cells weremeasured.Results: Mean endothelial cell densities before and 3 months after surgery were 2,240.37 SD347.92 cells/mm2 (range: 1,020 to 2,703) and 2,283.86 SD 425.13 cells/mm2 (range: 1,001 to2,837), respectively. Mean coefficient of variation before and 3 months after surgery were32.63 SD 4.65 (range: 22 to 48) and 33.00 SD 4.75 (range: 23 to 51), respectively. Meanpercentage of hexagonal cells before and 3 months after surgery were 54.58 SD 6.60 (range:46 to 71) and 55.26 SD 8.89 (range: 38 to 76), respectively. No statistically significantdifferences were found in any of the parameters studied when compared to thepreoperative values.Conclusions: A single intraoperative application of 0.02% MMC for 1 minute duringpterygium simple excision surgery does not seem to cause substantial changes in cornealendothelial cell density at 3 months(AU)